CN107233351A - A kind of pharmaceutical composition for treating Alzheimer formula syndrome and application - Google Patents
A kind of pharmaceutical composition for treating Alzheimer formula syndrome and application Download PDFInfo
- Publication number
- CN107233351A CN107233351A CN201710491373.7A CN201710491373A CN107233351A CN 107233351 A CN107233351 A CN 107233351A CN 201710491373 A CN201710491373 A CN 201710491373A CN 107233351 A CN107233351 A CN 107233351A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- alzheimer formula
- kaempferitrin
- swertiamarin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to a kind of pharmaceutical composition for treating Alzheimer formula syndrome and application；The pharmaceutical composition is formulated comprising following raw materials according：Kaempferitrin, Swertiamarin, 1,8 dihydroxy anthraquinones；With to treatment Alzheimer formula syndrome effect, substantially, Quality Control is stable, with low cost, Nantural non-toxic, and is suitable to the advantage of long-term taking.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of pharmaceutical composition for treating Alzheimer formula syndrome and
Using.
Background technology
Alzheimer formula syndrome is a kind of continuation higher nerve functional activity obstacle, i.e., in the shape without the disturbance of consciousness
Under state, the obstacle in terms of memory, thinking, analysis judgement, visual space identification, mood.
Main principle of reatment includes：1. it is metabolized activating agent (ubiquinone with brain10, CDPC) and Brain circlulation accelerator
(hyderginum, flunarizine) activation brain metabolism, suppresses dull-witted development indirectly.Brain is metabolized activating agent mainly by promoting grape
Sugar absorbs, metabolism, and secondary expansion of cerebral vascular improves Nutrition and Metabolism, and Brain circlulation accelerator is the medicine of direct expansion of cerebral vascular；
2. the medicine of nerve transmission block is treated, such as amantadine can promote dopamine D_2 receptors, suppress its reuptake；Calcium hopantenate can promote
The intracerebral for entering glucose absorbs and is metabolized, serotonin concentration and cerebral blood flow (CBF) in increase brain tissue, hence it is evident that improve nervous symptoms；
Acetylcholine precursor medicine (lecithin, Choline Chloride) and cholinesterase inhibitor (eserine, tetrahydrochysene amido pyridine) are by increasing
Plus the function of acetylcholine system, improve nervous symptoms；Neuropeptide can improve the elderly's understanding, memory capability, mitigate depressed
With powerless symptom；3. symptomatic treatment, commonly uses the control Alzheimer formula syndrome such as Methotrexate, fluphenazinum, fluorine croak butanol and suffers from
Person's irritability and aggressive behavior；Conventional ritalin, chlorine ester acyl improve Alzheimer formula syndrome patients' depressive symptom；Conventional stabilize changes
Kind Alzheimer formula syndrome patients' anxiety symptom.
The content of the invention
It is an object of the invention to overcome defect of the prior art stable there is provided a special quality control, safely and effectively, natural nothing
A kind of pharmaceutical composition for treating Alzheimer formula syndrome of poison and application.
The object of the present invention is achieved like this：The pharmaceutical composition is formulated comprising following raw materials according：Kaempferitrin, river deer tooth
Dish hardship glycosides, 1,8- dihydroxy anthraquinones.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：10~100 parts of Kaempferitrin, 10~100 parts of Swertiamarin, 7~100 parts of 1,8- dihydroxy anthraquinones.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：10~80 parts of Kaempferitrin, 10~80 parts of Swertiamarin, 7~80 parts of 1,8- dihydroxy anthraquinones.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：10~50 parts of Kaempferitrin, 10~50 parts of Swertiamarin, 7~50 parts of 1,8- dihydroxy anthraquinones.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：20 parts of Kaempferitrin, 15 parts of Swertiamarin, 7 parts of 1,8- dihydroxy anthraquinones.
Present invention also offers aforementioned pharmaceutical compositions in the pharmaceutical composition for preparing treatment Alzheimer formula syndrome
Application.
Heretofore described Kaempferitrin, Swertiamarin, 1,8- dihydroxy anthraquinones can directly by being commercially available,
It can be obtained by plant extract.The present invention pulverizes and sieves above-mentioned raw materials respectively by weight, mixes, and loads capsule or pressure
It is made as tablet；Or mixed with pharmaceutically acceptable carrier or diluent, it is reloaded into capsule or is compressed to tablet.
It is present invention also offers the instructions of taking of described pharmaceutical composition, its dose is in terms of said composition：Adult, 20
~30mg/ times, 3 times/day；Children, 10~15mg/kg times, 3 times/day, you can reach that treatment Alzheimer formula syndrome is clinical
The effect of symptom, especially, the special population such as pregnant woman need to be followed the doctor's advice when taking, and its special adverse reaction is not yet found at present.This
The described treatment of invention means the treatment after morbidity, and the intervention of premorbid is not represented.
Heretofore described Kaempferitrin, molecular formula is C27H3O14, molecular weight is 578.52；Subformula is：
Heretofore described Swertiamarin, molecular formula is C16H22O10, molecular weight is 696.82；Molecular structural formula is：
Heretofore described 1,8- dihydroxy anthraquinones, molecular formula is C14H8O4, molecular weight is 240.21.Molecular structural formula
For：
According to research find, Kaempferitrin, Swertiamarin, 1,8- dihydroxy anthraquinones composition compound can effectively suppress Ah
Er Haimoshi syndrome rat nerve tissues morphological changes, improve the cognition, study and note of Alzheimer formula syndrome rat
Recall ability, hence it is evident that mitigate Alzheimer formula syndrome, therapeutic effect better than ergometrine, CDPC, calcium hopantenate,
Amantadine, lecithin.
Alzheimer formula syndrome can be effectively improved by keeping away dark experiment by rat step down test, rat and demonstrating the present invention
The cognition of rat, learning and remembering ability, therapeutic effect are better than ergometrine, CDPC, calcium hopantenate, amantadine, ovum
Phosphatide.
Found by om observation, the present invention can substantially suppress three layers of Alzheimer formula syndrome CA 1 of Hippocampus cone
Body cell arrangement disorder, cones's swelling, cell infiltration, proliferation of astrocytes, segmented cone cell body diminish
Or the extension of triangular in shape, apical dendrite, karyopycnosis and rupture, the thermophilic Yihong color of endochylema, matrix it is loose with micro- vacuolization, blood vessel around
The morphological change such as there is red blood cell to ooze out.
The present invention has to treatment Alzheimer formula syndrome effect substantially, and Quality Control is stable, with low cost, Nantural non-toxic,
And suitable for the advantage of long-term taking.
Brief description of the drawings
Fig. 1 is present invention influence (light morphologic on Alzheimer formula syndrome CA 1 of Hippocampus cortex cones
Mirror 0.8K ×) schematic diagram.
Embodiment
The present invention be a kind of pharmaceutical composition for treating Alzheimer formula syndrome and application, wherein, the pharmaceutical composition
It is formulated comprising following raw materials according：Kaempferitrin, Swertiamarin, 1,8- dihydroxy anthraquinones.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：10~100 parts of Kaempferitrin, 10~100 parts of Swertiamarin, 7~100 parts of 1,8- dihydroxy anthraquinones.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：10~80 parts of Kaempferitrin, 10~80 parts of Swertiamarin, 7~80 parts of 1,8- dihydroxy anthraquinones.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：10~50 parts of Kaempferitrin, 10~50 parts of Swertiamarin, 7~50 parts of 1,8- dihydroxy anthraquinones.
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：20 parts of Kaempferitrin, 15 parts of Swertiamarin, 7 parts of 1,8- dihydroxy anthraquinones.
Present invention also offers aforementioned pharmaceutical compositions in the pharmaceutical composition for preparing treatment Alzheimer formula syndrome
Application.
In order to more clearly explain the present invention, it is further described in conjunction with specific embodiment.It is specific real
Under applying for example：
Embodiment one
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：9 parts of Kaempferitrin, 101 parts of Swertiamarin, 6.5 parts of 1,8- dihydroxy anthraquinones.
Embodiment two
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：102 parts of Kaempferitrin, 9 parts of Swertiamarin, 101 parts of 1,8- dihydroxy anthraquinones.
Embodiment three
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：101 parts of Kaempferitrin, 102 parts of Swertiamarin, 6.3 parts of 1,8- dihydroxy anthraquinones.
Example IV
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：10 parts of Kaempferitrin, 10 parts of Swertiamarin, 7 parts of 1,8- dihydroxy anthraquinones.
Embodiment five
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：100 parts of Kaempferitrin, 100 parts of Swertiamarin, 100 parts of 1,8- dihydroxy anthraquinones.
Embodiment six
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：55 parts of Kaempferitrin, 55 parts of Swertiamarin, 53.5 parts of 1,8- dihydroxy anthraquinones.
Embodiment seven
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：80 parts of Kaempferitrin, 80 parts of Swertiamarin, 80 parts of 1,8- dihydroxy anthraquinones.
Embodiment eight
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：45 parts of Kaempferitrin, 45 parts of Swertiamarin, 43.5 parts of 1,8- dihydroxy anthraquinones.
Embodiment nine
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：80 parts of Kaempferitrin, 10 parts of Swertiamarin, 55 parts of 1,8- dihydroxy anthraquinones.
Embodiment ten
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：50 parts of Kaempferitrin, 50 parts of Swertiamarin, 50 parts of 1,8- dihydroxy anthraquinones.
Embodiment 11
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：30 parts of Kaempferitrin, 30 parts of Swertiamarin, 28.5 parts of 1,8- dihydroxy anthraquinones.
Embodiment 12
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：10 parts of Kaempferitrin, 50 parts of Swertiamarin, 18 parts of 1,8- dihydroxy anthraquinones.
Embodiment 13
A kind of pharmaceutical composition for treating Alzheimer formula syndrome, the pharmaceutical composition is comprising following raw materials according according to weight
Number is formulated：20 parts of Kaempferitrin, 15 parts of Swertiamarin, 7 parts of 1,8- dihydroxy anthraquinones.
Above-described embodiment is only intended to clearly illustrate example of the present invention, and the not restriction to embodiment.
For the general technical staff of art, other various forms of changes can also be made on the basis of the above description
Or change.There is no necessity and possibility to exhaust all the enbodiments, and the obvious change thus amplified out
Or among changing still in the invention scope of the claims.
The present invention can be prepared into various various forms of medicaments by Kaempferitrin, Swertiamarin, 1,8- dihydroxy anthraquinones,
Such as：The forms such as aqueous solvent, powder and mixture；When needing to prepare aqueous solvent medicine is weighed according to following weight：Kaempferitrin 20mg,
Swertiamarin 30mg, 1,8- dihydroxy anthraquinone 15mg, are dissolved in tri-distilled water, packing.When needing to prepare powder according to
Lower weight weighs medicine：Kaempferitrin 20g, Swertiamarin 30g, 1,8- dihydroxy anthraquinone 15g, mixing, packing.Work as needs
When preparing mixture medicine is weighed according to following weight：Kaempferitrin 20g, Swertiamarin 30g, 1,8- dihydroxy anthraquinones 15g, point
Dress, filling capsule.
Experimental example 1
Detection the present invention to rat diving tower, keep away the influence secretly tested；
1st, raw material：Kaempferitrin, Swertiamarin, 1,8- dihydroxy anthraquinones above-mentioned raw materials are by the limited public affairs of the emerging commerce and trade of Shanghai section
Department purchases；Hyderginum is purchased by Shanghai Hua Tai medicine companies limited company；CDPC is by Suzhou heavenly steed fine chemistry
Product limited company purchases；Calcium hopantenate is purchased by Shanghai Jia Lun bio tech ltd；Amantadine is by Shijiazhuang City
Three and pharmaceutcal corporation, Ltd purchase；Lecithin is purchased by Guangzhou Bang Li bio tech ltd.
2nd, instrument：Rat diving tower record system is purchased by Huaibei Zhenghua Biological Instrument Co., Ltd., rat keeps away dark instrument
Purchased by Huaibei Zhenghua Biological Instrument Co., Ltd..
3rd, animal：Sprague-Dawley (SD) rat, 6 week old, male, 180~220g, cleaning grade are tested by Henan Province
Animal center is provided.
4th, experiment packet：(1) blank control group：Healthy SD rat 20, daily early morning empty stomach tri-distilled water gavage, gavage is held
Measure as 10ml/kg, continuous gavage 8 weeks；(2) Alzheimer formula syndromes models group：It is big that 2VO methods prepare Alzheimer formula syndrome
Mouse model 20；(3) of the present invention group of low dosage：Alzheimer formula syndromes models rat 20, daily early morning is sent out with this on an empty stomach
Bright solution gavage, gavage concentration 5mg/kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks；(4) the middle dosage present invention
Group：Alzheimer formula syndromes models rat 20, daily early morning empty stomach solution gavage of the present invention, gavage concentration 10mg/kg,
Gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks；(5) of the present invention group of high dose：Alzheimer formula syndromes models rat
20, daily early morning uses solution gavage of the present invention on an empty stomach, and gavage concentration 20mg/kg, gavage capacity is administered for 10ml/kg, continuously
Gavage 8 weeks；(6) hyderginum group：Alzheimer formula syndromes models rat 20, daily early morning empty stomach hyderginum
Solution gavage, gavage concentration 2.0mg/kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks；(7) CDPC group：
Alzheimer formula syndromes models rat 20, daily early morning uses CDPC solution gavage, gavage concentration 1.0mg/ on an empty stomach
Kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks；(8) calcium hopantenate group：Alzheimer formula syndromes models rat 20
Only, daily early morning uses calcium hopantenate solution gavage on an empty stomach, and gavage concentration 2mg/kg, gavage capacity is administered for 10ml/kg, continuous to fill
Stomach 8 weeks；(9) amantadine group：Alzheimer formula syndromes models rat 20, daily early morning is filled with amantadine solution on an empty stomach
Stomach, gavage concentration 0.5mg/kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks；(10) lecithin group：Alzheimer formula
Syndromes models rat 20, daily early morning uses lecithin soln gavage, gavage concentration 0.2mg/kg on an empty stomach, and gavage capacity is
10ml/kg is administered, continuous gavage 8 weeks.
5th, experiment content：Rat step down test, rat keep away dark experiment.
6th, statistical method：All data are with mean ± standard deviationRepresent.Group difference compare with ANOVA and
Newman-Student Multiple range tests；T check analyses, are completed by the statistical softwares of SPSS 13.0, and bilateral P ＜ 0.05 think difference
There is conspicuousness.
7th, result
Influence of 7.1 present invention to rat step down test：Result of the test shows that the present invention can significantly improve the examination of rat diving tower
Test incubation period, reduce errors number, and with significant dose dependent；With hyderginum, CDPC, homopantothenic acid
Calcium, amantadine, lecithin control group compare, and there is obvious difference (P ＜ 0.05).(the results are shown in Table 1)
The present invention of table 1 can be to Alzheimer formula syndrome rat step down test influence
Note：Compared with Alzheimer formula syndromes models group, * P ＜ 0.05；Of the present invention group is compared with high dose, # ＜
0.05。
7.2 present invention keep away the influence secretly tested to Alzheimer formula syndrome rat：Result of the test shows that the present invention can be bright
Aobvious raising Alzheimer formula syndrome rat keeps away dark experiment incubation period, reduces errors number, and with significant dose-dependant
Property；Compared with hyderginum, CDPC, calcium hopantenate, amantadine, lecithin control group, there is obvious difference
(P ＜ 0.05).(the results are shown in Table 2)
The present invention of table 2 keeps away the influence secretly tested to Alzheimer formula syndrome rat
Note：Compared with Alzheimer formula syndromes models group, * P ＜ 0.05；Of the present invention group is compared with high dose, # ＜
0.05。
Experimental example 2
The detection present invention is to CA 1 of Hippocampus cones's Morphology Effects.
1st, raw material：Kaempferitrin, Swertiamarin, 1,8- dihydroxy anthraquinones above-mentioned raw materials are by the limited public affairs of the emerging commerce and trade of Shanghai section
Department purchases.
2nd, instrument：TS1000 Nikon microscopes.
3rd, animal：SD rats, 6 week old, male, 180~220g, cleaning grade, are provided by experimental animal center of henan province.
4th, experiment packet：Packet：(1) Normal group：Healthy SD rat 20, daily early morning is filled with tri-distilled water on an empty stomach
Stomach, gavage capacity is 10ml/kg, continuous gavage 8 weeks；(2) Alzheimer formula syndromes models group：2VO methods prepare Alzheimer
Formula syndrome rat model 20；(3) of the present invention group is taken：Alzheimer formula syndromes models rat 20, daily early morning is empty
Abdomen solution gavage of the present invention, gavage concentration 10mg/kg, gavage capacity is administered for 10ml/kg, continuous gavage 8 weeks；
5th, experiment content：Morphological observation under light microscopic.
6th, result：The present invention is on the morphologic influence of Alzheimer formula syndrome CA 1 of Hippocampus cortex cones
(light microscopic 0.8K ×).As shown in figure 1, the cones's arrangement of three layers of Alzheimer formula syndromes models group CA 1 of Hippocampus is disorderly
Disorderly；Segmented cone cellular swelling, and have cell infiltration, proliferation of astrocytes；Segmented cone cell body diminishes or is in
Triangle, apical dendrite extension has karyopycnosis and fracture phenomena, and endochylema is in uniform thermophilic Yihong color；Segmented cone cell nuclear shoals,
Matrix is loose with micro- vacuolization；There is red blood cell to ooze out around blood vessel, indivedual visible thin vessels hyperplasia.Taking of the present invention group can be bright
Aobvious to suppress hippocampus CA1 cones's morphological change, cellular morphology is normal, it is seen that typical three confluent monolayer cells arrangement.In Fig. 1
Shown Normal group is 1；Alzheimer formula syndromes models group is 2；It is 3 to take present invention group.
Heretofore described pharmaceutically acceptable carrier or the form of diluent and feature are by by mixed work
Property the amount of composition, method of administration, physiological disposition (including absorb, distribution, metabolism, excretion) and other known variable institute is really
It is fixed.Necessarily " acceptable ", i.e., they should can be adapted to these carriers with other compositions of preparation, not interfere with the effect of said preparation
Fruit and the recipient for being not detrimental to said preparation.For example, used pharmaceutical carriers can be solid or liquid.Solid is carried
The example of body is lactose, carclazyte, sucrose, talcum powder, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid, poly-
Ethylene glycol, polyvinylpyrrolidone, collagen hydrolysate etc..The example of liquid-carrier be phosphate buffered saline solution, syrup,
Emulsion, wetting agent, sterile solution etc..Similarly, carrier or diluent may include time delay material well known in the art, such as individually
Glycerin monostearate or distearin or the mixture with wax.Large-scale medicament forms can be used.Therefore,
If using solid carrier, said preparation can be placed on hard gelatine capsule, into lozenge or sugar with piece agent, with powder or particle form
The form of ingot.The change of the amount of solid carrier will be very big, but preferably about 50mg to about 1g.When using liquid-carrier, preparation
Can be into syrup, emulsion, the form of soft gelatine capsule.
Claims (6)
1. a kind of pharmaceutical composition for treating Alzheimer formula syndrome, it is characterised in that：The pharmaceutical composition includes following original
Material is formulated：Kaempferitrin, Swertiamarin, 1,8- dihydroxy anthraquinones.
2. a kind of pharmaceutical composition for treating Alzheimer formula syndrome according to claim 1, it is characterised in that：The medicine
Compositions are formulated comprising following raw materials according according to parts by weight：10~100 parts of Kaempferitrin, 10~100 parts of Swertiamarin,
1,8- 7~100 parts of dihydroxy anthraquinone.
3. a kind of pharmaceutical composition for treating Alzheimer formula syndrome according to claim 1, it is characterised in that：The medicine
Compositions are formulated comprising following raw materials according according to parts by weight：10~80 parts of Kaempferitrin, 10~80 parts of Swertiamarin, 1,
7~80 parts of 8- dihydroxy anthraquinones.
4. a kind of pharmaceutical composition for treating Alzheimer formula syndrome according to claim 1, it is characterised in that：The medicine
Compositions are formulated comprising following raw materials according according to parts by weight：10~50 parts of Kaempferitrin, 10~50 parts of Swertiamarin, 1,
7~50 parts of 8- dihydroxy anthraquinones.
5. a kind of pharmaceutical composition for treating Alzheimer formula syndrome according to claim 1, it is characterised in that：The medicine
Compositions are formulated comprising following raw materials according according to parts by weight：20 parts of Kaempferitrin, 15 parts of Swertiamarin, 1,8- dihydroxy
7 parts of anthraquinone.
6. a kind of pharmaceutical composition as described in claim any one of 1-5 is preparing the medicine for the treatment of Alzheimer formula syndrome
Application in composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710491373.7A CN107233351A (en) | 2017-06-07 | 2017-06-07 | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710491373.7A CN107233351A (en) | 2017-06-07 | 2017-06-07 | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107233351A true CN107233351A (en) | 2017-10-10 |
Family
ID=59986673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710491373.7A Pending CN107233351A (en) | 2017-06-07 | 2017-06-07 | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107233351A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3943085A3 (en) * | 2018-05-24 | 2022-02-23 | ETH Zurich | Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases, atherosclerosis, hepatitis b infection and human papilloma virus (hpv) infection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102046176A (en) * | 2008-05-29 | 2011-05-04 | 阿尔巴尼分子研究公司 | 5-HT3 receptor modulators, methods of making, and use thereof |
| CN105237598A (en) * | 2015-09-24 | 2016-01-13 | 安徽农业大学 | Flavone oxygen glycoside compound named as camellikaempferoside B, and preparation method and applications thereof |
-
2017
- 2017-06-07 CN CN201710491373.7A patent/CN107233351A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102046176A (en) * | 2008-05-29 | 2011-05-04 | 阿尔巴尼分子研究公司 | 5-HT3 receptor modulators, methods of making, and use thereof |
| CN105237598A (en) * | 2015-09-24 | 2016-01-13 | 安徽农业大学 | Flavone oxygen glycoside compound named as camellikaempferoside B, and preparation method and applications thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈巧霞等: "山茱萸功能性成分的提取分离及生物活性研究进展", 《江苏中医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3943085A3 (en) * | 2018-05-24 | 2022-02-23 | ETH Zurich | Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases, atherosclerosis, hepatitis b infection and human papilloma virus (hpv) infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rai et al. | A double-blind, placebo controlled study of Ginkgo biloba extract (‘tanakan’) in elderly outpatients with mild to moderate memory impairment | |
| Barrett et al. | Assessing the risks and benefits of herbal medicine: an overview of scientific evidence | |
| CN102548571A (en) | Compositions and methods for prevention and treatment of brain diseases and conditions | |
| Hu et al. | Effect and safety of hydroxysafflor yellow A for injection in patients with acute ischemic stroke of blood stasis syndrome: A phase II, multicenter, randomized, double-blind, multiple-dose, active-controlled clinical trial | |
| CN107233351A (en) | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and application | |
| CN102302730B (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands | |
| CN107789349A (en) | Treat pharmaceutical composition and its application of Alzheimer syndrome | |
| CN107233347A (en) | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application | |
| CN106860472A (en) | A kind of pharmaceutical composition for treating Alzheimer formula syndrome and its application | |
| CN105943651A (en) | Traditional Chinese medicine composition for treating premature ovarian failure, and application thereof | |
| CN106924226A (en) | A kind of pharmaceutical composition for treating atherosclerosis and application | |
| CN106237268B (en) | It is a kind of to treat schizoid pharmaceutical composition and its application | |
| CN105147709B (en) | A kind of purposes of tenofovir dipivoxil or its pharmaceutical salts | |
| CN103751207B (en) | The pharmaceutical composition for the treatment of Alzheimer formula syndrome and application thereof | |
| CN107802634A (en) | A kind of pharmaceutical composition for treating Alzheimer syndrome and its application | |
| CN107050005A (en) | A kind of pharmaceutical composition for treating atherosclerosis and its application | |
| CN107397751A (en) | Treat pharmaceutical composition and its application of Alzheimer formula syndrome | |
| CN107802636A (en) | A kind of pharmaceutical composition for treating Alzheimer's disease and its application | |
| CN106668037A (en) | Pharmaceutical composition for treating Alzheimer's syndrome and application | |
| CN106667993A (en) | Pharmaceutical composition for treating Alzheimer's syndrome and application | |
| CN106667999A (en) | Pharmaceutical composition for treating Alzheimer's syndrome and application thereof | |
| CN103751206A (en) | Medicinal composition for preventing Alzheimer's disease and application thereof | |
| CN106074507A (en) | Pharmaceutical composition that prevention of arterial is atherosis and application thereof | |
| WO2020233459A1 (en) | Composition for improving memory and preparation method therefor | |
| Ghassab-Abdollahi et al. | The effect of mullein capsule on uterine leiomyomas volume and the amount of menstrual bleeding: a randomized controlled trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171010 |